Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Defibrotide treatment in VOD/SOS patients

Mohamad Mohty • 7 Dec 2020
ASH 2020
General Defibrotide
DEFIFrance

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the DEFIFrance study. This study collected real-world data on the safety and effectiveness of defibrotide in France in patients with veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after hematopoietic stem cell transplantation (HSCT). The efficacy and safety observed in this study support the utility of defibrotide for treating severe/very severe VOD/SOS post-HSCT in a real-world setting. Its findings highlight the importance of prompt diagnosis and continued treatment until full resolution of symptoms is achieved. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Mohamad Mohty

CERVINO trial results and the potential role of etentamig in multiple myeloma
1:19
CERVINO trial results and the potential role of etentamig in multiple myeloma
Mohamad Mohty • 24 Sep 2026
IMS 2026 highlights: evolving multiple myeloma treatment and the path toward cure
7:00
IMS 2026 highlights: evolving multiple myeloma treatment and the path toward cure
Mohamad Mohty • 24 Sep 2026
Transitioning bispecifics into community care for myeloma: recently published guidelines
5:44
Transitioning bispecifics into community care for myeloma: recently published guidelines
Mohamad Mohty • 13 Jun 2026
Key highlights from COMy 2026: quadruplet regimens, CAR-T, bispecifics, trispecifics, and more
8:13
Key highlights from COMy 2026: quadruplet regimens, CAR-T, bispecifics, trispecifics, and more
Mohamad Mohty • 15 May 2026

Related Videos

Key principles for implementing AI tools into clinical practice
3:19
Key principles for implementing AI tools into clinical practice
Adrián Mosquera Orgueira • 24 Sep 2026
Current role of AI in hematology/oncology: separating the hype from reality
2:54
Current role of AI in hematology/oncology: separating the hype from reality
Adrián Mosquera Orgueira • 24 Sep 2026
Addressing the risk of over-reliance on AI for clinical decision-making
2:25
Addressing the risk of over-reliance on AI for clinical decision-making
Adrián Mosquera Orgueira • 24 Sep 2026
Telomere dynamics in normal and pathological aging
12:41
Telomere dynamics in normal and pathological aging
Coleman Lindsley • 18 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals